Channeled endomural therapy
AssigneeEndoluminal Therapeutics, Inc.
InventorMarvin Slepian
Life of this patent
Estimating the term…
Loading patent…
AssigneeEndoluminal Therapeutics, Inc.
InventorMarvin Slepian
Estimating the term…
Diseases, aging, trauma, environmental exposure, infection and other events or agents can alter tissue function. In one embodiment, treatment is provided by therapeutically altering tissue function. This may be by continuing normal tissue function, suppressing tissue function, or enhancing tissue function. In a preferred embodiment, this treatment is effectuated by penetrating an organ, organ component or tissue structure and placing a supplemental material in a newly created space. This space is generally referred to herein as a “privileged space”, i.e. a space not otherwise present in native tissue. Supplemental materials can be deposited and secured within the zone. Supplemental materials include materials forming barriers, supports, and/or materials that deliver agents having a pharmacologic, biochemical, or physiologic effect in vivo. Suitable supplemental materials include polymeric and non-polymeric materials, pharmacologic agents, cells, tissue fragments, microorganisms, viral agents, or other reagents modifying tissue function. The supplemental material is typically in the form of a reservoir/depot, or continuous or discontinuous layer. In one embodiment, supplemental materials, and methods of use thereof, are provided for the continuous or discontinuous therapy of defined regions of an organ, organ component or tissue structure. The supplemental materials may be delivered directly to any one or more of the three zones, endoluminal (or ectomural, for solid organs), endomural, or ectoluminal, of organs, organ components, or tissue structures. The supplemental materials can include natural or synthetic polymeric materials that are biodegradable or non-biodegradable. The supplemental materials can also contain bioactive agents to effectuate a change in an organ or organ component in need thereof. For example, agents that result in a reduced/hyponormal response or an amplified/hypernormal response may be included in the supplemental materials.
A method of treating diseases, aging, trauma, environmental exposure, infection and other events or agents that alter tissue function in an organ, organ component or tissue structure comprising
A system for treating diseases, aging, trauma, environmental exposure, infection and other events or agents that alter tissue function in an organ, organ component or tissue structure, the system comprising
A method for the therapeutic treatment of an organ, organ component or tissue structure in an animal, comprising applying a supplemental material comprising a bioactive agent to one or more regions of the organ, organ component or tissue structure.
Dependencies are inferred from the claim text.